Exascale Labs Holdings Inc. (Class A) (XLAB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Exascale Labs Holdings Inc. (Class A) (NASDAQ: XLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.84 (-9.84% 1D, market cap $202.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 714 tracked Technology issuers, XLAB ranks #590 in composite RQD confidence.
Within the Technology sector (Computer Software: Prepackaged Software), XLAB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 15.8%, and ROIC of -23.7%. By comparison, DUOT (Duos Technologies Group Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -15.9%, cap $203.3M) and GIBO (GIBO Holdings Limited (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $192.2M). Among the 5-stock peer group, XLAB leads on earnings multiple (N/A) while DUOT leads on capital efficiency (-15.9% ROIC).
Per XLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0002109869), Exascale Labs Holdings Inc. (Class A) generated $7.0M in revenue, -$7.7M in net income, and -$1.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While XLAB currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Technology with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.01) and Max Pain ($2.98) forces dealer call-delta covering toward $11.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Exascale Labs Holdings Inc. (Class A) (XLAB) dropped -9.84% to $2.84, trading at 20% of its 52-week range ($0.78 – $11.17). Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.
Stocktwits report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Gainers Braiin (NASDAQ:BRAI) stock increased by 90.1% to $4.03 during Tuesday's regular session. The company's market cap stands at $436.9 million. AudioEye (NASDAQ:AEYE) shares rose 33.96% to $9.94. The
Gainers ClearOne (NASDAQ:CLRO) stock rose 63.5% to $3.14 during Friday's regular session. The company's market cap stands at $4.7 million. BIO-key International (NASDAQ:BKYI) shares rose 32.1% to $3.62. The
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XLAB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XLAB. Explore sector supply chains on /butterfly.
Across 714 tracked Technology securities in the Roarable RQD universe, Exascale Labs Holdings Inc. (Class A) (XLAB) ranks #590 by composite RQD confidence (31/100, grade E) and #476 by equity capitalization ($202.7M). Within this direct 5-issuer industry benchmark cohort, XLAB leads on earnings valuation at N/A trailing P/E, while DUOT leads on capital efficiency and profitability with -15.9% ROIC and 29.2% gross margin. EXFY currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with XLAB at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XLAB
ACTIVE
Exascale Labs Holdings Inc. (Class A) | E | 31/100 | — | 15.8% | -23.7% | -9.84% | $202.7M | Benchmark Subject |
| DUOT Duos Technologies Group Inc. | E | 32/100 | — | 29.2% | -15.9% | -4.03% | $203.3M | /duot-vs-xlab → |
| GIBO GIBO Holdings Limited (Class A) | D+ | 52/100 | — | — | -35.0% | +17.91% | $192.2M | /gibo-vs-xlab → |
| ZENA ZenaTech Inc. | D | 46/100 | — | — | — | -5.52% | $185.8M | /zena-vs-xlab → |
| EXFY Expensify Inc. (Class A) | D+ | 53/100 | — | 50.3% | -20.4% | -3.29% | $221.6M | /exfy-vs-xlab → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Exascale Labs Holdings Inc. (Class A) (XLAB) reported GAAP revenue of $7.0M , GAAP net income of -$7.7M, operating cash flow of -$1.0M, and free cash flow of -$1.0M . On the balance sheet, XLAB closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $7.0M | -$7.7M | -$1.0M | -$1.0M | — | — |
As of 2026-11-02, Exascale Labs Holdings Inc. (Class A) (NASDAQ: XLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.84 (-9.84% 1D, market cap $202.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 714 tracked Technology issuers, XLAB ranks #590 in composite RQD confidence.
Within the Technology sector (Computer Software: Prepackaged Software), XLAB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 15.8%, and ROIC of -23.7%. By comparison, DUOT (Duos Technologies Group Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -15.9%, cap $203.3M) and GIBO (GIBO Holdings Limited (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $192.2M). Among the 5-stock peer group, XLAB leads on earnings multiple (N/A) while DUOT leads on capital efficiency (-15.9% ROIC).
Per XLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0002109869), Exascale Labs Holdings Inc. (Class A) generated $7.0M in revenue, -$7.7M in net income, and -$1.0M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Technology with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XLAB last traded at $2.84 (-9.84% on volume of 383,222 shares), positioning the stock -5.65% below its 50-day simple moving average ($3.01) and -64.50% below its 200-day simple moving average ($8.00). Across its 52-week range of $0.78 to $11.17, XLAB sits at the 19.8% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.49 to $3.19).
Why XLAB Stock dropped -9.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD Score is 31 out of 100, graded E, with a verdict of "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). Across the five pillars:
For a prospective investor evaluating the stock today, the upside case rests on a company with a very wide trading range and recent news flow, while the downside case is anchored in negative returns, negative margins, and weak forensic scores. The price-to-value tradeoff cannot be measured precisely because earnings-based valuation multiples are not available in source data. Investors weighing this name should treat the RQD verdict as a risk-control signal and focus research on whether the cash-flow and returns gap can close.
Exascale Labs Holdings Inc. (Class A) is a NASDAQ-listed issuer in the Technology sector, Computer Software: Prepackaged Software industry (per the company profile). The source data does not describe its specific products, customer base, or revenue model. The company reported FY 2025 revenue of $7.0M (per the SEC financials), and gross margin of 15.8% (per the market data).
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-06-30) | $7.0M | $-3.0M | $-7.7M | N/A | $-1.0M | N/A | N/A |
Per the market data, operating margin is -43.4% and net margin is -60%, with ROIC at -23.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, which indicates weak fundamental quality. The reported Debt/Equity ratio is 0.5 (per the Roarable RQD rating). Cash and debt figures in the SEC financials are listed as N/A, so balance-sheet liquidity cannot be fully assessed from the source data.
Six news items are provided (per the recent news and catalysts feed), all relating to XLAB market action and coverage. Three are labeled "MARKET WIRE" with a YELLOW signal and one is labeled "CATALYST" with a GREEN signal (Simply Wall St, asking whether the company is positioned to deliver on growth plans). Two items are generic market-data pages (Stocktwits market cap query and Moomoo options chain page). A kalkine.ca item reports a 6.7% decline after a "wild swing." The feed does not contain specific product, contract, or earnings events. Risk watch items include the sharp price volatility implied by the 52-week range and the recent decline cited in the kalkine.ca headline. No proprietary signals are present in the Butterfly graph.
Real-time company headlines, analyst actions, and sector developments for Exascale Labs Holdings Inc. (Class A) (XLAB) • Click "Debate This Headline" to argue it in the Roar Pit below
Stocktwits report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Exascale Labs Holdings Inc. (Class A) (XLAB) market action, institutional positioning, and fundamental catalysts.
Welcome to the XLAB (Exascale Labs Holdings Inc. (Class A)) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Computer Software: Prepackaged Software. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on XLAB, but look at what you are paying: current EV/EBITDA multiples with 15.8% gross margins. Unless Exascale Labs Holdings Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on XLAB, the market is fixating on short-term headline noise in Computer Software: Prepackaged Software and ignoring the balance sheet and cash flow trajectory. At $3.15 (52-wk range $0.78 - $11.17), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).